ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / TLRY / financials
OBIO (34) SNDL (47) CGC (41) USNA (50) ⌘ Pro Terminal →

Tilray Brands Inc. (TLRY) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$2.55 +0.79% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.55

Tilray Brands Inc. (TLRY) carries a Roarable Rating of E (Strong Sell) with 19/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $373.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TLRY Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TLRY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Tilray Brands Inc. (NASDAQ: TLRY) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $2.55 (+0.79% 1D, market cap $373.9M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, TLRY ranks #992 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TLRY compare to OBIO and SNDL in the Health Care sector?
▼

Within the Health Care sector (Medicinal Chemicals and Botanical Products), TLRY carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of 28.4%, and ROIC of -3.9%. By comparison, OBIO (Orchestra BioMed Holdings Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $355.2M) and SNDL (SNDL Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $301.7M). Among the 5-stock peer group, USNA leads on earnings multiple (24.6x) while USNA leads on capital efficiency (7.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TLRY?
▼

Per TLRY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-05-31, CIK 0001731348), Tilray Brands Inc. generated $915.5M in revenue (+11.5% YoY), -$121.4M in net income, and -$69.1M in free cash flow against $2.07B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.55 (-0.05%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (19/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510019
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (3)Whales (3)SEC (8)Macro (3)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-17.6% Base Target
$16 Bull$2 Base$2 Bear
📬 FREE TLRY RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TLRY)Realized 20D OHLCV Swing Band: ±10.6%
Deterministic 5-Pillar Attribution (19/100 Composite)
🔍 WHY TLRY SCORES 19/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (42% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Cash Engine Quality+4/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 28.4% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
27
Grade E$3.27-7.3% Next Q
Q2 (-2Q)
24
Grade E$3.03-8.6% Next Q
Q3 (-1Q)
22
Grade E$2.77-7.9% Next Q
Current
19
Grade E$2.55-12% Hist 90D α
Trajectory: E (27) → E (19)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TLRY Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TLRY currently carries a cautious 19/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.70) and Max Pain ($2.68) forces dealer call-delta covering toward $16.48.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TLRY• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TLRY Beats Next Quarter EPS Consensus (Nov 29, 2026) & Holds Above 200D SMA”
YES 19%NO 81%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How TLRY Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$915.5MGross Profit $260.4M (28.4%)Cost of Sales $655.0MOp Profit $0 (0%)OpEx (R&D/SG&A) $260.4MNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow
FY23
Rev $788.9M
FY24
Rev $821.3M
FY25
Rev $915.5M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$915.5M28.4%-6.9%-$121.4M-$69.1M-3.9%
FY 2024$821.3M29.3%-80%-$2.19B-$94.6M-45%
FY 2023$788.9M28.4%-22.1%-$245.0M-$30.9M-3.9%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TLRY)

  • ✓Walkthrough of TLRY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
TLRY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -56.78%🛡️ HOLDING TREND SUPPORT
2026-11-03O $2.64H $2.64L $2.53C $2.55VOL 4.93M
RES: $4.34SUP: $2.45SMA50: $3.70SMA200: $5.40
$10.28$8.17$6.06$3.95$1.83RES $4.34SUP $2.45$2.552026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TLRY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TLRY Butterfly Map → + Track TLRY →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +11.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on TLRY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TLRY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TLRY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TLRY)

Health Care Rank #992 of 1015 ⚔️ OBIO vs TLRY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TLRY vs. OBIO, SNDL, CGC, USNA)

Industry: Medicinal Chemicals and Botanical Products (23 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Tilray Brands Inc. (TLRY) ranks #992 by composite RQD confidence (19/100, grade E) and #483 by equity capitalization ($373.9M). Within this direct 5-issuer industry benchmark cohort, USNA leads on earnings valuation at 24.6x trailing P/E, while USNA leads on capital efficiency and profitability with 7.9% ROIC and 78.3% gross margin. USNA currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with TLRY at 19/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
TLRY ACTIVE
Tilray Brands Inc.
E 19/100 — 28.4% -3.9% +0.79% $373.9M Benchmark Subject
OBIO
Orchestra BioMed Holdings Inc.
E 34/100 — 96.0% -35.0% -3.72% $355.2M /obio-vs-tlry →
SNDL
SNDL Inc.
D 47/100 — — — +2.42% $301.7M /sndl-vs-tlry →
CGC
Canopy Growth Corporation
D- 41/100 — — — +4.34% $276.0M /cgc-vs-tlry →
USNA
USANA Health Sciences Inc.
D 50/100 24.6x 78.3% 7.9% +2.87% $264.4M /usna-vs-tlry →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-05-31 • CIK 0001731348 ↗

In its most recent audited fiscal period (FY2025, filed 2026-05-31), Tilray Brands Inc. (TLRY) reported GAAP revenue of $915.5M (+11.5% vs. FY2024 revenue of $821.3M , and +16.0% cumulative change since FY2023) , GAAP net income of -$121.4M, operating cash flow of -$69.1M, and free cash flow of -$69.1M (+26.9% YoY). On the balance sheet, TLRY closed FY2025 with $2.07B in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-05-31 $915.5M -$121.4M -$69.1M -$69.1M $2.07B —
FY2024 (FY) 2025-05-31 $821.3M -$2.19B -$94.6M -$94.6M $3.40B —
FY2023 (FY) 2024-05-31 $788.9M -$245.0M -$30.9M -$30.9M — —

3. TLRY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TLRY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Tilray Brands Inc. (NASDAQ: TLRY) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $2.55 (+0.79% 1D, market cap $373.9M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, TLRY ranks #992 in composite RQD confidence.

How does TLRY compare to OBIO and SNDL in the Health Care sector?

Within the Health Care sector (Medicinal Chemicals and Botanical Products), TLRY carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of 28.4%, and ROIC of -3.9%. By comparison, OBIO (Orchestra BioMed Holdings Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $355.2M) and SNDL (SNDL Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $301.7M). Among the 5-stock peer group, USNA leads on earnings multiple (24.6x) while USNA leads on capital efficiency (7.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TLRY?

Per TLRY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-05-31, CIK 0001731348), Tilray Brands Inc. generated $915.5M in revenue (+11.5% YoY), -$121.4M in net income, and -$69.1M in free cash flow against $2.07B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TLRY trading relative to its 50-day, 200-day, and 52-week technical levels?

TLRY last traded at $2.55 (+0.79% on volume of 4,615,965 shares), positioning the stock -31.08% below its 50-day simple moving average ($3.70) and -52.78% below its 200-day simple moving average ($5.40). Across its 52-week range of $2.49 to $15.70, TLRY sits at the 0.5% percentile with a 14-day RSI of 23.5 (OVERSOLD (<32)) and an implied next-earnings move of ±10.6% ($2.28 to $2.82).

Direct Sub-Reports: TLRY RQD Cockpit TLRY 12M Forecast TLRY Earnings & Move TLRY Dividends & DRIP TLRY Insiders & 13F TLRY Whale Options TLRY Profit Sankey TLRY News & Why
ROARABLE RATING BRIEF • RQD 19/100 (E) ✓ SEC XBRL & RQD VERIFIED

TLRY — Tilray Brands Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-05-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Tilray Brands Inc. (TLRY) earns a live Roarable RQD composite score of 19/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.55 (+0.79% 1D, market capitalization $373.9M).

  • Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -3.9%, gross margin of 28.4%, operating margin of -6.9%, and free cash flow yield of -17.72%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (3/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 5/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Tilray Brands Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Medicinal Chemicals and Botanical Products industry. The profile identifies the company as having a market capitalization of $0.4B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-05-31), Tilray Brands Inc. (TLRY) reported $915.5M in annual revenue (up from $821.3M in FY2024, +11.5% YoY) and -$121.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($788.9M revenue, -$245.0M net income) through FY2025, TLRY scaled operating cash flow to -$69.1M and free cash flow to -$69.1M, backed by $2.07B in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 19/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -17.72% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.49 – $15.70 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -6.9% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Sector correlation and second-order bottlenecks cannot be mapped from the provided material. The only sector context available is the Health Care classification and the Medicinal Chemicals and Botanical Products industry,. An investor should treat the absence of mapped supply-chain links as an open gap rather than evidence of an absence of exposure.

  • Key Question #1: Can TLRY sustain or expand its -6.9% operating margin and -3.9% ROIC against Medicinal Chemicals and Botanical Products peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $915.5M and free cash flow of -$69.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is TLRY's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

TLRY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Tilray Brands Inc. (TLRY) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TLRY Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TLRY Bull vs. Bear Conversation Board — What's Your Call at $2.55?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TLRY 🐻 33% BEARISH CONVICTION
1. Pick Your Side on TLRY:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $3.34 (+32.0%)
📌 Pinned Debate

Revenue grew from $788.9M in FY 2023 to $915.5M in FY 2025 and the forensic balance sheet pillar is the strongest of the five at 8/20.

Long TLRY at $2.53 targeting $3.34. Revenue grew from $788.9M in FY 2023 to $915.5M in FY 2025 and the forensic balance sheet pillar is the strongest of the five at 8/20.. Institutional whale score is 3/20 and the risk/reward vs. the $2.49 52-week low is skewed heavily in favor of bulls.

SectorRotator 🐂 BULL

@BreakoutHunter Agree on the RQD 19/100 quality, though with 1.0 beta I'm scaling in with half-size at $2.53 and keeping dry powder in case we test $2.35.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $2.00 (-20.9%)
Spot @ $2.53

The RQD Score of 20 with a Fundamental Cash Engine pillar of 2/20, an FCF yield of -17.72%, and an Altman Z of 0.2 signals forensic ris

Sitting on the sidelines or leaning short TLRY above $2.53. The RQD Score of 20 with a Fundamental Cash Engine pillar of 2/20, an FCF yield of -17.72%, and an Altman Z of 0.2 signals forensic risk.. Until Fundamental Cash Engine (2/20) and FCF yield (-17.72%) inflect higher, upside is capped near $15.70.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%